Company news

SanBio Co., Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Notice Regarding Conclusion of a Committed Credit Line Agreement with Resona Bank, Limited and Expansion of Borrowing Facility

October 30, 2026

Presentation for Financial Results for the 2nd Quarter of the Fiscal Year Ending January 31, 2027

September 17, 2026

[Delayed] Consolidated Financial Results for the Six Months Ended July 31, 2026 [Japanese GAAP]

September 15, 2026

Notice Concerning Recording of Non-operating Income,Non-operating Expenses and Deferred Income Taxes

September 14, 2026

[Delayed] Notice Regarding Integration of AKUUGO(R) Manufacturing Operations in Japan Following Closure of Minaris’ U.S. Facility

September 7, 2026

[Delayed]Notice Concerning Recording of Non-operating Income and Deferred Income Taxes

June 16, 2026

Consolidated Financial Results for the Three Months Ended April 30, 2026[Japanese GAAP]

June 15, 2026

SanBio Obtains Marketing Approval for AKUUGO Suspension for Intracranial Implantation as a Therapeutic Agent for Improving Chronic Motor Paralysis from Traumatic Brain Injury

August 1, 2024

SanBio Obtains Marketing Approval for “AKUUGO® Suspension for Intracranial Implantation” (INN: Vandefitemcel) as a Therapeutic Agent for Improving Chronic Motor Paralysis From Traumatic Brain Injury (TBI)

July 31, 2024

Announcement on Granting Stock Options (Share Acquisition Rights)

August 16, 2022

Notice regarding appointment of new corporate officers

August 1, 2022

Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan

July 22, 2022

Keizo Nakada to Join SanBio as Corporate Officer and Head of Production

July 1, 2022

Recording of Non-operating Income (Foreign Exchange Gains), Deferred Income Taxes, and Short-Term Loans Payable

June 15, 2022

SanBio: Consolidated Financial Results for the Three Months Ended April 30, 2022

June 14, 2022

Andrew Liu to Join SanBio as Chief Strategy Officer

June 1, 2022

SB623 Demonstrated Sustained Improvement in Motor Impairment up to 48 Weeks and Associated with Improvement

April 5, 2022

SB623 Demonstrated Sustained Improvement in Motor Impairment up to 48 Weeks and Associated with Improvement in Function and Activities of Daily Living in Patients with Chronic Traumatic Brain Injury

April 5, 2022

［Delayed］Recording of Non-Operating Expenses (Financing Expenses)

March 23, 2022

Partial Amendment to the Articles of Incorporation, Reduction in Amounts of Stated Capital and Capital Reserves and Appropriation of Capital Surplus

March 11, 2022

SanBio: Announcement on Issuance Plans of Stock Options (Share Acquisition Rights)

March 11, 2022

Presentation for Financial Results for the Fiscal Year Ending Jan.31, 2022

March 11, 2022

SanBio: Consolidated Financial Results for the Fiscal Year Ended January 31, 2022

March 11, 2022

SanBio: Notice Regarding Completion of Approval Filing for Japan SB623 Chronic TBI Program

March 7, 2022

Notice regarding completion of approval filing for Japan SB623 chronic TBI program

March 7, 2022

SanBio: Consolidated Financial Results for the Nine Months Ended October 31, 2021

December 16, 2021

Notice on the recording of other comprehensive income, non-operating income, and non-operating expenses

December 15, 2021

Notice on Conclusion of Committed Credit Line Agreement with Resona Bank Ltd.

December 15, 2021

SanBio Joins the Newly Formed National TBI Registry Coalition (NTRC) as a Founding Member Organization

December 15, 2021

Business Partnership for Development and Commercialization of Regenerative Medicine MSC2

November 16, 2021

Business Partnership for Development and Commercialization of Medical Device Implant Utilizing MSC2 for the Regeneration of Esophageal Tissue in Humans

November 16, 2021

SanBio Announces Publication Comparing Outcome Measures for Persons With Chronic Traumatic Brain Injury in Expert Review of Neurotherapeutics

November 1, 2021

Decks